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Purpose: This study aims to describe a 12-month medication adherence with oral
anticancer medications (OAMs) in a routine care medication adherence program, and
to better characterize non-persistence.
Patients and methods: In this observational, one-centered, longitudinal study,
medication adherence was monitored electronically while patients were taking part in
a medication adherence program for 12 months or until treatment stop. Patients were
>18 years and starting or taking one of the following OAMs: letrozole, exemestane,
imatinib, sunitinib, capecitabine, or temozolomide. Non-persistence was defined as any
premature treatment interruption due to patient’s unilateral decision or to a medical
decision because of adverse effects. The Kaplan Meier survival function estimate was
used to characterize persistence, and Generalized Estimating Equations (GEE) were
adopted to fit implementation. Statistical analyses were performed using the R software
package.
Results: Forty-three outpatients with various tumor entities were enrolled. Reasons for
quitting the medication adherence program and/or OAM medication were characterized
as OAM discontinuation due to adverse effects or toxicity (n = 5), planned OAM
completion time (n = 10), OAM failure (cancer relapse) (n = 5) and non-compliance to
the adherence program (n = 3). In persistent patients, the implementation rates were
high (from 98% at baseline to 97% at 12 months). The probability of being persistent at
12 months was estimated at 85%.
Conclusion: A better characterization of both persistence and implementation to OAMs
in real life settings is crucial for understanding and optimizing medication adherence to
OAMs. The complex identification of non-persistence underlines the need to carefully and
prospectively assess OAM interruption or treatment switch reasons. The GEE analysis
for describing implementation to OAMs will allow researchers and professionals to take
advantage of the richness of longitudinal real-time data, to avoid reducing such data
through thresholds and to put them into perspective with OAM blood levels.
Keywords:medication adherence (MeSH), electronicmonitoring (EM), oral treatments, oncology, non-persistence,
routine care, censoring, generalized estimating equations (GEE)
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INTRODUCTION
Cancer treatments used to be administered solely by intravenous
(i.v.) infusions during patients’ hospital visits. The increasing
availability and use of oral anticancer medications (OAMs) has
shifted patient therapy schemes from outpatient oncology units
to home-administered settings.
Anticancer therapy investigations are making outstanding
approaches available to enhance efficiency by focusing,
for example, on targets. As a result of scientific progress,
cancer patients’ life expectancies have improved substantially,
and changed the disease and thus the medications from
acute to chronic treatments, e.g., in breast cancer, leukemia,
gastrointestinal stromal tumor (GIST). Chronic cancer patients
face major new challenges, such as the optimization of long-term
adherence to cancer medication under orally administrated
regimens (Sabate, 2003; Ruddy et al., 2009; Weingart et al., 2010;
Wood, 2012; Timmers et al., 2014). However, data on adherence
to OAMs in real life settings remain scarce.
Compared to inpatient intravenous (i.v.) administration,
OAMs are associated with improved quality of life for patients,
as they eliminate the need for invasive drug administration,
enhancing patients’ autonomy, and responsibility and allowing
home-treatment (Ruddy et al., 2009). Nonetheless, the narrow
therapeutic index of OAMs requires close monitoring of adverse
effects to ensure treatment safety, and a high medication
adherence to ensure treatment efficacy.
Medication adherence is considered as an overall definition
including treatment initiation, implementation and persistence
(Vrijens et al., 2012). The implementation characterizes the
day-by-day drug intake during the period of persistence.
Persistence is defined as the time period from treatment
initiation until discontinuation. Even if no “gold standard”
measurement method exists, electronic monitoring (EM)
represents the most accurate method to capture the
dynamic and longitudinal characteristics of drug intake
(Krummenacher et al., 2010; Lehmann et al., 2014; Nguyen et al.,
2014).
Published OAM adherence rates were reported to vary largely,
i.e., from 16 to 100%, and included mainly clinical trials data
(Partridge et al., 2002, 2003; Bhattacharya et al., 2012; Allen
and Williamson, 2014; Barillet et al., 2015). Rates differed
according to cancer type and stage, and according to used
adherence measurement methods. Determinants associated with
non-implementation and non-persistence in cancer patients are
complex and interrelated (Cheung et al., 2015; Verbrugghe
et al., 2016). In breast cancer, for example, non-persistence
is predominantly caused by treatment-related adverse effects,
longer-term therapies and age (Verbrugghe et al., 2016). Sub-
optimal implementation and persistence rates of long-term
OAMs in routine care are particularly problematic, as the
border between medication toxicity and cancer progression due
to inadequate plasma concentrations is not well established.
Additionally, considering the constantly increasing number of
prescribed targeted OAMs, non-adherence needs to be better
characterized and knowledge needs to be transferred into practice
in order to support patient-tailored and interprofessional
adherence interventions in oncology (Hershman et al., 2011;
Ibrahim et al., 2011; Al-Barrak and Cheung, 2013).
The pharmacy of the Department of Ambulatory Care
& Community Medicine in Lausanne (PMU) runs an
interprofessional medication adherence program (IMAP)
(Lelubre et al., 2015). Medication adherence to each drug is
monitored via electronic monitoring, combined with manual pill
count and feedback to the patients. This study aims to describe
a 12-month adherence -persistence and implementation-
to different OAMs in a routine care medication adherence
program, and intends to better characterize discontinuation and
non-persistence by analyzing reasons for discontinuation.
METHODS
This is a one-center, observational, longitudinal study approved
by the Ethics Committee of Canton de Vaud, Switzerland
(Protocol Nr: 261/07). Informed and written consent was
obtained from all study participants. Inclusion criteria were:
patients older than 18 years, starting or taking an on-going OAM,
ability to use electronic monitoring (EM) devices, and absence of
severe psychiatric or social disorders, or language barrier.
Following OAMs were included with their respective intake
schemes: letrozole (aromatase inhibitor) 2.5mg QD on a
continuous scheme; exemestane (aromatase inhibitor) 25mg QD
on a continuous scheme; imatinib (tyrosine kinase inhibitor)
400, 600, or 800mg a day, QD or BID on a continuous scheme;
sunitinib (tyrosine kinase inhibitor) 37.5mg QD on a continuous
scheme or 50mg QD 4 weeks on/2 weeks off; temozolomide
(alkylating agent) 75 mg/m2/day concomitantly to radiotherapy
or 250 mg/m2/day, 5 days on/3 weeks off; or capecitabine
(5-fluorouracil prodrug) 2,000–2,500 mg/m2/day BID 2 weeks
on/1 week off. Neither a dose change in regimen, nor a switch
between OAMs during the 12-month study was a criterion for
participant’s withdrawal.
The exploratory analysis was based on the enrolment of a
convenient sample of approximately 40 consecutive participants.
Participants were monitored for 12 months or until treatment
stop with participants’ study visits scheduled at inclusion, at 3,
6, 9, and 12 months.
Medication adherence was monitored electronically. All
participants used EM with an electronic display on top (MEMS
SmartCapTM, Medication Event Monitoring System, AARDEX
Group, Sion, Switzerland; Krummenacher et al., 2010; Lehmann
et al., 2014; Lelubre et al., 2015). EM consists of an electronic
device that records and stores the date and time of each
pill container opening. The electronic display on top of EM
informs the patient in real time on the number of daily pill-
bottle openings (e.g., 0, 1, 2, etc.). At each study visit, EM
results were printed in a report format, which summarizes
graphically the drug intake since the last study visit, and were
discussed with each participant (Lelubre et al., 2015). To increase
reliability, electronic data were reconciled according to an
operational manual previously described (Rotzinger et al., 2016).
Reconciliation with pill count and interview notes allowed for the
addition of confirmed pocket doses to the electronic adherence
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data, i.e., a dose that the patient removes from the pillbox to
swallow later.
All consecutive patients were enrolled by the hospital
oncologists whatever their level of adherence and referred to
the pharmacists of the Department of Ambulatory Care &
Community Medicine in Lausanne (PMU) (Lelubre et al., 2015).
Each prescribed OAM was dispensed in a separate EM device
according to good pharmaceutical practices. At inclusion, the
correct use of the EM device was explained and opportunity to
practice was given. Missed study visits at the adherence clinic
were rescheduled.
Participants’ socio-demographic characteristics, clinical and
treatment data were collected at baseline by reviewing the
medical and pharmacy records.
The ABC European adherence initiative taxonomy of
persistence, implementation and adherence was used in this
study (Vrijens et al., 2012) as described below:
1) “Persistence” was defined as the distribution of times until
OAM discontinuation. OAM discontinuation was defined
here as a medication stop due to either the patient own,
unilateral decision or a medical decision because of an OAM
adverse effect or toxicity. Stops due to OAM failure or planned
end of treatment (completion, cancer remission, surgery, or
prescribed switch to other iv oncology or radiology therapies),
due to non-compliance to the medication adherence program
without medication discontinuation (participants quitting the
medication adherence study), as well as the end of the 1 year
observation period were considered as censoring.
2) “Implementation” at day x was expressed as the number
of participants who took at least the prescribed medication
dosing regimen at day x divided by the number of participants
not having discontinued, nor being censored before that day
(Blaschke et al., 2012).
3) “Adherence” at day x represented the number of participants
who took at least the prescribed medication dosing regimen at
day x divided by the number of participants initially included
into the study.
Data Analysis
Classical descriptive statistics were used to describe socio-
demographic data at baseline, and clinical data at baseline
and at exit. Numbers and percentages were adopted to
characterize binary and categorical variables; median and
1st and 3rd quartiles were used to summarize quantitative
variables.
Implementation was plotted against time and compared
with the number of participants still under observation
(neither discontinuing, nor censored) at each day x. Persistence
was estimated using the Kaplan Meier survival function of
discontinuation times.
Censored durations before the end of the observation period
represented a challenge in calculating adherence. By definition,
a censored participant is a participant who will experience
discontinuation somewhere in the future, without information
on the exact time. Thus, a censored patient will certainly
continue taking medication for a period after the censoring
date, but daily adherence during this period is unknown since
patient is no more under observation. In addition, the possibility
of a discontinuation before the end of the study, with a
subsequent null adherence, cannot be excluded. A somehow
natural solution could consist in considering adherence after
censoring as missing (naive adherence curve). Unfortunately,
the resulting adherence would be inconsistent with the Kaplan
Meier estimate of persistence. The latter in fact jumps only
when a discontinuation occurs, the size of each jump depending
on the number of censoring having occurred before each
discontinuation (Zhang et al., 2009), while the naive adherence
curve drops at discontinuations and (to a lower extent) at
censoring times, leading to an estimate of adherence at the end
of follow up systematically lower than the Kaplan Meier estimate
of persistence. Persistence representing at a given day the
proportion of participants not having discontinued at that day,
adherence must coincide with this proportion if implementation
is perfect (= 100%) on that day (adherence = persistence).
Since this is not true for the naive adherence curve (adherence
< persistence), we conclude that the latter represents a biased
estimate of adherence.
Therefore, the presence of censoring prevents us from
calculating adherence directly from censored data. We propose
here to estimate adherence indirectly as the product, for each
follow-up time, between implementation and the Kaplan Meier
estimate of persistence (i.e., implementation∗persistence). Such a
solution, which gives the same results as the empirical adherence
in an ideal situation where there is no censoring, was considered
as the optimal one in our setting, where adherence cannot be
calculated directly on data because of censoring.
Generalized Estimating Equations (GEE) with an
“independence” correlation structure were adopted in order to fit
implementation. Time was entered into themodel using “splines”
(two knots at 4 and 8 months), allowing a flexible estimation of
the implementation pattern across time. Confidence intervals
around implementation were obtained using a robust estimation
of the covariance matrix of the model parameters.
Statistical analyses were performed using the R software
package (R Core Team, 2013).
RESULTS
A total of 51 patients were eligible. Eight patients refused to
participate in the study; six were not interested, one individual
considered the study as too inconvenient and one elderly
individual did not feel at ease with EM handling. Thus, the study
included 43 participants.
The study lasted from March 2008 to October 2011, and
provided 12’081 cumulated days of observations (openings of
EM device). Participants’ socio-demographic data at baseline,
and clinical data at baseline and exit are summarized in Table 1.
The majority of participants [median age 62 (52–69), 53%
women] was naive to treatment (88%) and was diagnosed with
gastrointestinal stromal tumor or breast cancer. Median time
length between cancer diagnosis and study initiation was seven
months.
The reasons for quitting the medication adherence program
and/or OAM medication before the 12-month completion of
the observation period are illustrated in Figure 1. Among
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FIGURE 1 | Reasons for medication adherence program stop and/or OAM stop.
FIGURE 2 | Implementation. Empirical curve and fit obtained with GEE model.
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FIGURE 3 | Adherence and persistence. Blue curve: Kaplan Meier estimator of persistence: it represents an estimate of the percentage of patients not having
discontinued as a function of time. Pink curve: Adherence obtained multiplying implementation and persistence: it represents an estimate of the daily percentage of
patients, among those initially included into the study, correctly taking the prescribed medication.
the 23 participants (23/43 inclusions, 53%) having quitted
the medication adherence program, 5 OAM discontinuation
cases were identified, all due to adverse effects or toxicity. Of
these five, one participant decided to discontinue his OAM
unilaterally without any medical agreement and four participants
discontinued their OAM with medical agreement. The array of
adverse effects was quite large from acute renal failure, severe
mental health problems, oedema, unstable angina, and insomnia.
Eighteen participants having quitted the adherence programwere
censored due to following reasons: (i) 10 cases of OAM planned
completion time, (ii) 5 cases of OAM failure, (iii) 3 cases of non-
compliance to the IMAPmedication adherence program but with
OAM continuation.
Figure 2 shows implementation over time. Implementation
remained stable but with an increase in variability. The latter was
due to the decrease of the number of participants from n = 43
at baseline to n = 20 at the end of the 12-month observation
period. Estimated implementation according to the GEE model
ranges from 98% (97–99%) at baseline to 97% (91–99%) at
the end of the observation period. Persistence and adherence
are represented in Figure 3. One can identify two specific time
periods for discontinuation: the first 3 discontinuation events are
responsible for the first decline happening within 60 days after
study and OAM initiations; the last 2 discontinuation events are
responsible for the second decline during the second semester of
treatment. The probability of being persistent at 12 months was
estimated at 85% (73% - 99%).
DISCUSSION
This study described a 12-month adherence -persistence and
implementation- to different OAMs in a routine care medication
adherence program, and characterized precisely reasons for
discontinuation. While addressing these aims, this study had
to focus on the methodological challenges of addressing
adherence to OAMs. Indeed, the identification of the reasons
for discontinuation to OAMs in real life clinical practice
is challenging due to the high prevalence of permanent
OAM stop not caused by non-persistence but due to various
clinical decisions. Hence, this study describes persistence and
implementation to six different OAMs by analyzing the reasons
for treatment discontinuation. Two different time periods for
non-persistence have been illustrated (one post-initiation and
one in the second semester); they might suggest key critical
phases of OAMmedication adherence, highlighting the difficulty
for OAM post-initiation as well as OAM toxicity development
during the second semester of treatment. Further data and
information are needed to consolidate these early findings. In
persistent participants, the modeled implementation was high
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TABLE 1 | Participants socio-demographic data at baseline, and clinical data at baseline and at exit.
SOCIO-DEMOGRAPHIC DATA (N = 43)
Age (in years) median [Quartiles 25 and 75] 62 [52, 69]
Gender Women 23 53%
Men 20 47%
CLINICAL DATA AT BASELINE
Cancer types Gastrointestinal Stromal tumor 21 49%
Breast cancer 17 40%
Kidney cancer 4 9%
Brain cancer 1 2%
Duration (months) between diagnosis and start of the study
[median, IQR]
7 [2,27]
Study start within 2 months of treatment initiation Yes 31 72%
No 12 28%
MONITORED ORAL ANTICANCER TREATMENT (OAM)
Name of OAM1 (DCI) Capecitabine 10 24%
Letrozole 10 24%
Imatinib 9 20%
Sunitinib 7 16%
Exemestane 6 14%
Temozolomide 1 2%
Prescribed pharmacological regimen Once a day (QD) 33 76%
Twice a day (BID) 10 24%
Prescribed daily dose for each drug treatment Median ± (IQ) Capecitabine 2.8 g [2.0; 5.0]
Letrozole 2.5 g [2.5; 2.5]
Imatinib 400mg [400; 400]
Sunitinib 37.5mg [12.5; 56.25]
Exemestane 25mg [25; 25]
Temozolomide 130mg [130; 130]
Treatment scheme Continuous 37 86%
Cyclic 6 14%
Treatment line 1st treatment (naive patients) 38 88%
2nd treatment 3 7%
≥3rd treatment 2 5%
Purpose of the treatment Adjuvant 25 59%
Palliative 12 29%
Neo-adjuvant 5 12%
Type of concomitant cancer treatments Oral medication 1 2%
Intravenous therapy 8 20%
Radiotherapy 6 14%
None 27 64%
CLINICAL DATA AT THE END OF THE STUDY (AT 12 MONTHS OR UPON WITHDRAWAL FROM THE STUDY)
Disease prognosis Remission 26 60%
Partial tumor response 13 31%
Cancer progression 4 9%
1OAM, oral anticancer medication.
and remained stable over the 12-month observation period (from
98 to 97%), with an increase in variability.
Compared to other chronic diseases, treatment changes are
more likely in oncology. Long-term OAMs involve numerous
therapeutic changes due to treatment failure (e.g., resistance,
mutations), alternated treatment plans (e.g., neoadjuvant
treatments) or management of adverse events. Hence, the
complex identification of non-persistence underlines the need
to carefully and prospectively assess reasons for OAM stop or
switch. Non-persistence could be misrepresented if for example
interruption due to treatment completion or cancer relapse is
not taken into account. This study defined non-persistence as
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any premature treatment discontinuation due to participant’s
own, unilateral decision and/or because of adverse effects. This
definition is an attempt to put emphasis on adverse effects as
the main reason for OAM discontinuation (Bassan et al., 2014;
Kottschade and Lehner Reed, 2017).
The medication adherence GEE approach represents a
statistical analysis that allowed us to describe implementation
to OAM longitudinally over the study period. This modeling
approach was used to characterize the participants’ behavior
with their treatment in routine outpatient care during a
medication adherence programwhereas literature mainly focuses
on describing adherence in clinical trials within selected
participant groups, not representing routine care (Gebbia et al.,
2012; Jabbour et al., 2012; Krolop et al., 2013; Barthelemy et al.,
2015; Lam and Cheung, 2016). Moreover, this methodological
approach can be applied to analyze longitudinal, electronic
monitoring of adherence to other drugs and in other diseases.
In the community, persistence in various chronic disease
areas (e.g., diabetes, HIV, asthma) generally decreases with
time but non-persistence is often tangled up with non-
implementation.(Caro et al., 1999) In our study, persistence
declined with time but implementation remained stable in
persistent patients.
This study has some limitations. Firstly, the number of
participants (N = 43) as well as the period of data collection
(2008–2011) might limit the outreach of the study results.
Nevertheless, the monitored OAMs are still in use with similar
prescribing indications, arguing in favor of the applicability of
the findings. Moreover, the questioning about the reasons for
discontinuation is applicable to any current OAM. This question
still remains relevant, as it has been poorly researched in cancer
and chronic diseases so far and requires further investigation, for
example whether they vary in naive or experimented patients. It
would be important to verify these results in larger studies with
new, targeted OAMs in various cancer types. The challenge to
define non-persistence to OAMs in real practice is high, as a non-
negligible part of the treatment interruptions are independent
from a non-persistent behavior but could be falsely associated to
non-persistence. Secondly, we decided to analyze all side effects
and toxicity events as sources of non-persistence. This concept
needs to be further addressed in the literature and a precise
taxonomy for classifying reasons for discontinuation should be
established as a reference guide.
This study was not powered enough to establish the
associations between adherence to OAM and clinical outcomes.
This will be the next experimental step with a larger group
of participants, where the association between medication
adherence, pharmacokinetics, pharmacodynamics, and patient
outcomes will be investigated (Cardoso et al., 2018). Importantly,
this study reveals that we should pay attention to the type
of components—persistence or implementation- that we do
measure and avoid mixing both. In routine care research,
advanced statistical methods such as GEE are an interesting
and alternate analysis to the establishment of thresholds
for implementation, for example when such thresholds are
impossible to establish as they may vary across molecules, cancer
types, cancer stages, and may vary with time, for example, during
the semester after initiation vs. long term OAM use.
CONCLUSION
This study provides a first experience to estimate persistence and
implementation electronically to various OAMs in four different
cancer types. It points out the needs for both a better description
of OAM adherence, defined as persistence and implementation,
in real life practice and a better characterization of OAM
discontinuation. Those are crucial elements of knowledge for
understanding and strengthening research on OAM adherence.
Our specific attempt to better define reasons for non-persistence
offers new perspectives to increase the comparability of results
across studies. Finally, this study underlines the need to transfer
this knowledge into practice in order to support patient-
tailored interventions in adherence, especially for newer OAM
generations and in different types of cancers. Indeed, healthcare
providers should help each individual patient achieve the highest
personal level of adherence through educational patient-centered
programs, balancing efficacy with patient safety, and quality of
life. In the future, a better understanding of the relationship
between adherence to OAM and drug blood levels is important
to individualize the regimen and allow patients to get the best
efficacy and safety outcomes (Cardoso et al., 2018).
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